AMRI narrows losses on strong Q3

CMO AMRI ($AMRI) posted an 11% jump in revenue in the third quarter, cutting its net loss by about $3.8 million thanks to double-digit growth in large-scale manufacturing.

AMRI took a loss of $2.1 million in Q3, down from $5.9 million in the same period last year. Revenue climbed to $55.8 million, offsetting a decline in its discovery business with a 14% boost in AMRI's large-scale manufacturing unit. The company says it would have virtually broken even on the quarter if not for restructuring charges stemming from its closure of a plant in Hungary.

The CMO pulled in $9.4 million in royalty revenue, an increase of 45%, thanks largely to its API manufacturing and money it gets from sales of Sanofi's ($SNY) Allegra.

Looking forward, CEO Thomas D'Ambra said AMRI should be able to continue its growth, buoyed by the recent signing of a discovery pact with Knopp Biosciences and a contract extension with Shire ($SHPG). Furthermore, "we are actively pursuing several other opportunities with existing and new customers that could potentially provide AMRI with a stronger, more diverse business base as we enter 2013," D'Ambra said in a statement.

AMRI affirmed its annual revenue guidance, predicting 10% year-over-year growth, and the company says its SmartSourcing platform--an all-in-one option for drugmakers--will help drive it into the black.

- read AMRI's release

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.